Xeris Biopharma Holdings, Inc. (XERS) Stock Score, Valuation & Financial Research
Xeris Biopharma Holdings, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 26/100.
Quick answer for XERS
Xeris Biopharma Holdings, Inc. currently has a Wall Street Score of 26/100. The stored market price is $7.45. Its financial score is 24/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Xeris Biopharma Holdings, Inc. does
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeri
XERS financial snapshot
- Wall Street Score:
- 26/100
- Current price:
- $7.45
- Market capitalization:
- $1.29B
- Revenue:
- $314.9M
- Net income:
- $12.0M
- Free cash flow:
- $27.9M
- Cash:
- $111.8M
- Total debt:
- $37.3M
- EPS:
- 0.00
- P/E ratio:
- 2128.6x
- Financial score:
- 24/100
- Valuation score:
- 0/100
- Revenue score:
- 32/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $27.9M, showing positive cash generation.
- The balance sheet shows $111.8M of cash versus $37.3M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 24/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research XERS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.